Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer
A Phase I Study of Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine With Filgrastim Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University of Chicago
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Histologically or cytologically confirmed adenocarcinoma of the male or female breast (male or female) with gross, uncontrolled, unresectable breast and/or chest wall disease including:
- patients with locally advanced unresectable stage IIIa or IIIb;
- patients with locally recurrent (including locoregional lymph nodes) disease for which curative surgery is not thought possible
- patients with metastatic disease AND uncontrolled locoregional disease are eligible.
- Prior chemotherapy allowed, except for nitrosoureas and mitomycin chemotherapy or high dose chemotherapy with marrow or stem cell rescue.
- Prior palliative radiation to sites of metastases allowed (i.e. bone, brain, lung)
- 4 weeks since any prior treatments (excluding hormonal therapy). Concurrent hormonal therapy is not allowed.
- Aged 18 years or older
- CALGB performance status of 0 - 2
- Life expectance of at least 12 weeks
Initial Laboratory Data:
- ANC Count > 1500/mm3
- Platelet Count > 100,000/mm3
- Creatine ≤ 2.0 mg/dl
- Bilirubin ≤ 1.5 mg/dl
- ALT (SGPT) ≤ 3 times the upper limit of normal
- Signed informed consent
Exclusion Criteria:
- Prior breast or chest wall radiation is not allowed unless the proposed site radiation port does not overlap with prior ports
- Subjects must not be pregnant (females able to have children must have negative pregnancy test and agree to use adequate contraception)
- Patients with a documented hypersensitivity to E.coli derived proteins are excluded.
- No other serious medical condition such as uncontrolled infection that in the opinion of the investigators places patient at undue risk for study treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
feasibility of administering study therapy to limit skin toxicity
Time Frame: 4 weeks
|
4 weeks
|
|
dose-limiting toxicity
Time Frame: 4 weeks
|
4 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
overall survival
|
|
|
time to progression
|
|
|
response
Time Frame: 14 weeks
|
14 weeks
|
|
Bcl-2 detection by immunohistochemistry
Time Frame: 14 weeks
|
14 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- UCIRB 9849
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.